mepivacaine has been researched along with Drug Hypersensitivity in 45 studies
Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.
Drug Hypersensitivity: Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lidocaine hydrochloride is an amide-type local anesthetic, commonly used for facial plastic as well as other surgical procedures." | 5.27 | Anaphylactic reaction to lidocaine. ( Cave, RH; Kennedy, KS, 1986) |
| "During a routine dental appointment, a patient had an anaphylactic reaction to an injection of a local anesthetic, mepivacaine HCl 3% without a vasoconstrictor." | 3.66 | Anaphylaxis due to local anesthesia hypersensitivity: report of case. ( Seskin, L, 1978) |
| "A 38-year-old white woman developed left medical rectus myositis possibly due to an immune response to mepivacaine (Carbocaine) injected around her upper left first molar." | 3.66 | Vertical pendular nystagmus in chronic myositis of medial and lateral rectus. ( Goldberg, RT, 1978) |
| "Patients with drug allergy show a specific immune response to drugs." | 1.30 | Recognition of local anesthetics by alphabeta+ T cells. ( Hari, Y; Pichler, WJ; Schnyder, B; von Greyerz, S; Zanni, MP, 1999) |
| "In 87 of the 90 patients with suspected anaphylactoid reactions to local anesthetic agents, negative skin reactions to at least one of the agents allowed intrabuccal challenge and subsequent recommendation of an agent for future use." | 1.29 | Skin testing after anaphylactoid reactions to dental local anesthetics. A comparison with controls. ( Challacombe, SJ; Hodgson, TA; Shirlaw, PJ, 1993) |
| "Lidocaine hydrochloride is an amide-type local anesthetic, commonly used for facial plastic as well as other surgical procedures." | 1.27 | Anaphylactic reaction to lidocaine. ( Cave, RH; Kennedy, KS, 1986) |
| "Depression of respiration or total respiratory failure may occur due to blockade of the superficially located medullary chemoreceptors in the form of a high or total spinal block." | 1.25 | [Clinical and experimental contribution concerning the pathogenesis of acute life-threatening complications during neck anaesthesia]. ( Egger, G; Steinsiepe, KF; Stofer, AR; Ulrich, L, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (57.78) | 18.7374 |
| 1990's | 8 (17.78) | 18.2507 |
| 2000's | 7 (15.56) | 29.6817 |
| 2010's | 3 (6.67) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Selmanoglu, A | 1 |
| Güvenir, H | 1 |
| Celik, IK | 1 |
| Karaatmaca, B | 1 |
| Toyran, M | 1 |
| Civelek, E | 1 |
| Misirlioglu, ED | 1 |
| Kvisselgaard, AD | 1 |
| Melchiors, BB | 1 |
| Krøigaard, M | 1 |
| Garvey, LH | 1 |
| Sharma, V | 1 |
| Harper, NJ | 1 |
| Garcez, T | 1 |
| Arkwright, PD | 1 |
| Estrada, JL | 1 |
| Perez-Laiz, JL | 1 |
| Latasa, M | 1 |
| Rodríguez-Paredes, A | 1 |
| Hawkins, JM | 1 |
| Moore, PA | 1 |
| Cox, B | 1 |
| Durieux, ME | 1 |
| Marcus, MA | 1 |
| Berkun, Y | 1 |
| Ben-Zvi, A | 1 |
| Levy, Y | 1 |
| Galili, D | 1 |
| Shalit, M | 1 |
| Valladares Otero, G | 1 |
| Martínez Navas, A | 1 |
| Olmedo Granados, L | 1 |
| Echevarría Moreno, M | 1 |
| González-Delgado, P | 1 |
| Antón, R | 1 |
| Soriano, V | 1 |
| Zapater, P | 1 |
| Niveiro, E | 1 |
| Johnson, WT | 1 |
| DeStigter, T | 1 |
| Wahl, G | 1 |
| Hodgson, TA | 1 |
| Shirlaw, PJ | 1 |
| Challacombe, SJ | 1 |
| Broown, RS | 1 |
| Redden, RJ | 1 |
| Chan, JT | 1 |
| Cuesta-Herranz, J | 1 |
| de las Heras, M | 1 |
| Fernández, M | 1 |
| Lluch, M | 1 |
| Figueredo, E | 1 |
| Umpierrez, A | 1 |
| Lahoz, C | 1 |
| Bourezane, Y | 1 |
| Adessi, B | 1 |
| Didier, JM | 1 |
| Vuitton, DA | 1 |
| Laurent, R | 1 |
| Meechan, J | 1 |
| Zanni, MP | 1 |
| von Greyerz, S | 1 |
| Hari, Y | 1 |
| Schnyder, B | 1 |
| Pichler, WJ | 1 |
| Astarita, C | 1 |
| Gargano, D | 1 |
| Romano, C | 1 |
| Cutajar, M | 1 |
| Manguso, F | 1 |
| Montanaro, D | 1 |
| Napolitano, A | 1 |
| Pezzuto, F | 1 |
| Lo Schiavo, M | 1 |
| Altucci, P | 1 |
| Abbate, G | 1 |
| Brown, RS | 1 |
| Paluvoi, S | 1 |
| Choksi, S | 1 |
| Burgess, CM | 1 |
| Reece, ER | 1 |
| Seskin, L | 1 |
| Hiyoshi, K | 1 |
| Iwanaga, Y | 1 |
| Kado, K | 1 |
| Takeda, K | 1 |
| Goldberg, RT | 1 |
| Dry, J | 1 |
| Leynadier, F | 1 |
| Damecour, C | 1 |
| Pradalier, A | 1 |
| Herman, D | 1 |
| Grimes, DA | 1 |
| Cates, W | 1 |
| Weyandt, JA | 1 |
| Stofer, AR | 2 |
| Ulrich, L | 2 |
| Steinsiepe, KF | 2 |
| Egger, G | 2 |
| Diaz, PM | 1 |
| Klein, CE | 1 |
| Gall, H | 1 |
| Frigeri, S | 1 |
| Fiamminghi, L | 1 |
| Moniaci, D | 2 |
| Mozzati, M | 2 |
| Albera, G | 2 |
| Re, G | 2 |
| Parabita, SF | 1 |
| Shimai, N | 1 |
| Yokoyama, K | 1 |
| Falace, DA | 1 |
| Hill, JS | 1 |
| Kennedy, KS | 1 |
| Cave, RH | 1 |
| Sehhati, G | 1 |
| Frey, R | 1 |
| Mildner, R | 1 |
| Smith, RB | 1 |
| Everett, WG | 1 |
| Hauck, G | 2 |
| Petersohn, F | 1 |
| Henn, R | 1 |
| Henn, RH | 1 |
| Schmidt, I | 1 |
| Aldrete, JA | 1 |
| O'Higgins, JW | 1 |
| Ross, NM | 1 |
| Baumstark, RJ | 1 |
| Seldin, R | 1 |
| Rozelle, FR | 1 |
| Klaschka, F | 1 |
| Dhunér, KG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Evaluation of Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter[NCT05373862] | 40 participants (Actual) | Interventional | 2022-07-29 | Completed | |||
| Clinical Evaluation of Arrhythmia Mapping With the Multi-Electrode OPTRELL™ Mapping Catheter[NCT04983797] | 31 participants (Actual) | Interventional | 2021-08-25 | Completed | |||
| Clinical Evaluation of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter[NCT05970120] | 30 participants (Anticipated) | Interventional | 2023-09-05 | Recruiting | |||
| Assessing the Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage: a Randomized Controlled Trial[NCT03636451] | Phase 3 | 114 participants (Actual) | Interventional | 2018-10-29 | Completed | ||
| An Evaluation of the Paracervical Block for Pain Control in First Trimester Surgical Abortion[NCT01094366] | Phase 4 | 121 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with non-serious adverse events within 7 days of index procedure associated with the use of the OPTRELL catheter were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. (NCT04983797)
Timeframe: Up to 7 days of index procedure at Day 0
| Intervention | Participants (Count of Participants) |
|---|---|
| OPTRELL Mapping Catheter | 0 |
Number of participants with pre-ablation mapping and clinically indicated mapping performed with the OPTRELL catheter without resort to other mapping catheters were reported. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) |
|---|---|
| OPTRELL Mapping Catheter | 31 |
Number of participants with SAEs within 7 days of index procedure were reported. An AE is any untoward medical occurrence in a participant whether or not related to the investigational device. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT04983797)
Timeframe: Up to 7 days of index procedure at Day 0
| Intervention | Participants (Count of Participants) |
|---|---|
| OPTRELL Mapping Catheter | 3 |
Number of participants with SAEs within 7 days of index procedure related to the OPTRELL catheter were reported. An adverse event (AE) is any untoward medical occurrence in a participant whether or not related to the investigational device. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT04983797)
Timeframe: Up to 7 days of index procedure at Day 0
| Intervention | Participants (Count of Participants) |
|---|---|
| OPTRELL Mapping Catheter | 0 |
Number of responders for physician assessment for ability to characterize the tissue were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for ability to characterize the tissue. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compared to the PENTARAY catheter?: Score 1 | Compared to the PENTARAY catheter?: Score 2 | Compared to the PENTARAY catheter?: Score 3 | Compared to the PENTARAY catheter?: Score 4 | Compared to the PENTARAY catheter?: Score 5 | Compared to the PENTARAY catheter?: Score 6 | Compared to the PENTARAY catheter?: Score 7 | Compared to other competitive multielectrode catheters?: Score 1 | Compared to other competitive multielectrode catheters?: Score 2 | Compared to other competitive multielectrode catheters?: Score 3 | Compared to other competitive multielectrode catheters?: Score 4 | Compared to other competitive multielectrode catheters?: Score 5 | Compared to other competitive multielectrode catheters?: Score 6 | Compared to other competitive multielectrode catheters?: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 0 | 0 | 16 | 15 | 0 | 0 | 0 | 0 | 0 | 25 | 0 |
Number of responders with physician assessment for arrhythmogenicity were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for arrhythmogenicity. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compared to the PENTARAY catheter?: Score 1 | Compared to the PENTARAY catheter?: Score 2 | Compared to the PENTARAY catheter?: Score 3 | Compared to the PENTARAY catheter?: Score 4 | Compared to the PENTARAY catheter?: Score 5 | Compared to the PENTARAY catheter?: Score 6 | Compared to the PENTARAY catheter?: Score 7 | Compared to other competitive multielectrode catheters?: Score 1 | Compared to other competitive multielectrode catheters?: Score 2 | Compared to other competitive multielectrode catheters?: Score 3 | Compared to other competitive multielectrode catheters?: Score 4 | Compared to other competitive multielectrode catheters?: Score 5 | Compared to other competitive multielectrode catheters?: Score 6 | Compared to other competitive multielectrode catheters?: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 2 | 5 | 10 | 14 | 0 | 0 | 0 | 0 | 5 | 19 | 1 |
Number of responders for physician assessment for catheter design were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for catheter design in OPTRELL catheter for mapping. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ability to achieve electrode contact with cardiac tissue: Score 1 | Ability to achieve electrode contact with cardiac tissue: Score 2 | Ability to achieve electrode contact with cardiac tissue: Score 3 | Ability to achieve electrode contact with cardiac tissue: Score 4 | Ability to achieve electrode contact with cardiac tissue: Score 5 | Ability to achieve electrode contact with cardiac tissue: Score 6 | Ability to achieve electrode contact with cardiac tissue: Score 7 | Electrodes spacing: Score 1 | Electrodes spacing: Score 2 | Electrodes spacing: Score 3 | Electrodes spacing: Score 4 | Electrodes spacing: Score 5 | Electrodes spacing: Score 6 | Electrodes spacing: Score 7 | Electrode array coverage: Score 1 | Electrode array coverage: Score 2 | Electrode array coverage: Score 3 | Electrode array coverage: Score 4 | Electrode array coverage: Score 5 | Electrode array coverage: Score 6 | Electrode array coverage: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 1 | 0 | 2 | 2 | 18 | 8 | 0 | 1 | 0 | 0 | 0 | 13 | 17 | 0 | 1 | 0 | 0 | 0 | 9 | 21 |
Number of responders for physician assessment for catheter visualization were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for catheter visualization. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visualization under fluoroscopy: Score 1 | Visualization under fluoroscopy: Score 2 | Visualization under fluoroscopy: Score 3 | Visualization under fluoroscopy: Score 4 | Visualization under fluoroscopy: Score 5 | Visualization under fluoroscopy: Score 6 | Visualization under fluoroscopy: Score 7 | Visualization in CARTO 3: Score 1 | Visualization in CARTO 3: Score 2 | Visualization in CARTO 3: Score 3 | Visualization in CARTO 3: Score 4 | Visualization in CARTO 3: Score 5 | Visualization in CARTO 3: Score 6 | Visualization in CARTO 3: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 0 | 7 | 9 | 15 | 0 | 0 | 0 | 0 | 3 | 10 | 18 |
Number of responders for physician assessment for catheters interactions were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for catheters interactions. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| With CARTO 3 System: Score 1 | With CARTO 3 System: Score 2 | With CARTO 3 System: Score 3 | With CARTO 3 System: Score 4 | With CARTO 3 System: Score 5 | With CARTO 3 System: Score 6 | With CARTO 3 System: Score 7 | EP Lab recording equipment: Score 1 | EP Lab recording equipment: Score 2 | EP Lab recording equipment: Score 3 | EP Lab recording equipment: Score 4 | EP Lab recording equipment: Score 5 | EP Lab recording equipment: Score 6 | EP Lab recording equipment: Score 7 | Pacing equipment: Score 1 | Pacing equipment: Score 2 | Pacing equipment: Score 3 | Pacing equipment: Score 4 | Pacing equipment: Score 5 | Pacing equipment: Score 6 | Pacing equipment: Score 7 | Introducer tool on catheter: Score 1 | Introducer tool on catheter: Score 2 | Introducer tool on catheter: Score 3 | Introducer tool on catheter: Score 4 | Introducer tool on catheter: Score 5 | Introducer tool on catheter: Score 6 | Introducer tool on catheter: Score 7 | Sheath: Score 1 | Sheath: Score 2 | Sheath: Score 3 | Sheath: Score 4 | Sheath: Score 5 | Sheath: Score 6 | Sheath: Score 7 | Irrigation bag and tubing: Score 1 | Irrigation bag and tubing: Score 2 | Irrigation bag and tubing: Score 3 | Irrigation bag and tubing: Score 4 | Irrigation bag and tubing: Score 5 | Irrigation bag and tubing: Score 6 | Irrigation bag and tubing: Score 7 | ICD or other implantable devices: Score 1 | ICD or other implantable devices: Score 2 | ICD or other implantable devices: Score 3 | ICD or other implantable devices: Score 4 | ICD or other implantable devices: Score 5 | ICD or other implantable devices: Score 6 | ICD or other implantable devices: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 0 | 4 | 12 | 15 | 0 | 0 | 0 | 1 | 8 | 12 | 10 | 0 | 0 | 0 | 0 | 4 | 3 | 7 | 0 | 0 | 0 | 3 | 6 | 14 | 8 | 0 | 0 | 0 | 3 | 6 | 14 | 8 | 0 | 0 | 0 | 0 | 5 | 15 | 11 | 0 | 0 | 0 | 1 | 2 | 2 | 3 |
Number of responders for physician assessment for design and coverage for confirming PVI were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for design and coverage for confirming PVI. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compared to the PENTARAY catheter?: Score 1 | Compared to the PENTARAY catheter?: Score 2 | Compared to the PENTARAY catheter?: Score 3 | Compared to the PENTARAY catheter?: Score 4 | Compared to the PENTARAY catheter?: Score 5 | Compared to the PENTARAY catheter?: Score 6 | Compared to the PENTARAY catheter?: Score 7 | Compared to other competitive multielectrode catheters?: Score 1 | Compared to other competitive multielectrode catheters?: Score 2 | Compared to other competitive multielectrode catheters?: Score 3 | Compared to other competitive multielectrode catheters?: Score 4 | Compared to other competitive multielectrode catheters?: Score 5 | Compared to other competitive multielectrode catheters?: Score 6 | Compared to other competitive multielectrode catheters?: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 3 | 2 | 7 | 9 | 0 | 0 | 0 | 4 | 0 | 13 | 4 |
Number of responders for physician assessment for maneuverability & handling were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for maneuverability & handling. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ability to Deploy (Left Atrium): Score 1 | Ability to Deploy (Left Atrium): Score 2 | Ability to Deploy (Left Atrium): Score 3 | Ability to Deploy (Left Atrium): Score 4 | Ability to Deploy (Left Atrium): Score 5 | Ability to Deploy (Left Atrium): Score 6 | Ability to Deploy (Left Atrium): Score 7 | Ability to Deploy (Right Atrium): Score 1 | Ability to Deploy (Right Atrium): Score 2 | Ability to Deploy (Right Atrium): Score 3 | Ability to Deploy (Right Atrium): Score 4 | Ability to Deploy (Right Atrium): Score 5 | Ability to Deploy (Right Atrium): Score 6 | Ability to Deploy (Right Atrium): Score 7 | Ability to Deploy (Left Ventricle): Score 1 | Ability to Deploy (Left Ventricle): Score 2 | Ability to Deploy (Left Ventricle): Score 3 | Ability to Deploy (Left Ventricle): Score 4 | Ability to Deploy (Left Ventricle): Score 5 | Ability to Deploy (Left Ventricle): Score 6 | Ability to Deploy (Left Ventricle): Score 7 | Ability to Deploy (Right Ventricle): Score 1 | Ability to Deploy (Right Ventricle): Score 2 | Ability to Deploy (Right Ventricle): Score 3 | Ability to Deploy (Right Ventricle): Score 4 | Ability to Deploy (Right Ventricle): Score 5 | Ability to Deploy (Right Ventricle): Score 6 | Ability to Deploy (Right Ventricle): Score 7 | Ability to Maneuver (Left Atrium): Score 1 | Ability to Maneuver (Left Atrium): Score 2 | Ability to Maneuver (Left Atrium): Score 3 | Ability to Maneuver (Left Atrium): Score 4 | Ability to Maneuver (Left Atrium): Score 5 | Ability to Maneuver (Left Atrium): Score 6 | Ability to Maneuver (Left Atrium): Score 7 | Ability to Maneuver (Right Atrium): Score 1 | Ability to Maneuver (Right Atrium): Score 2 | Ability to Maneuver (Right Atrium): Score 3 | Ability to Maneuver (Right Atrium): Score 4 | Ability to Maneuver (Right Atrium): Score 5 | Ability to Maneuver (Right Atrium): Score 6 | Ability to Maneuver (Right Atrium): Score 7 | Ability to Maneuver (Left Ventricle): Score 1 | Ability to Maneuver (Left Ventricle): Score 2 | Ability to Maneuver (Left Ventricle): Score 3 | Ability to Maneuver (Left Ventricle): Score 4 | Ability to Maneuver (Left Ventricle): Score 5 | Ability to Maneuver (Left Ventricle): Score 6 | Ability to Maneuver (Left Ventricle): Score 7 | Ability to Maneuver (Right Ventricle): Score 1 | Ability to Maneuver (Right Ventricle): Score 2 | Ability to Maneuver (Right Ventricle): Score 3 | Ability to Maneuver (Right Ventricle): Score 4 | Ability to Maneuver (Right Ventricles): Score 5 | Ability to Maneuver (Right Ventricle): Score 6 | Ability to Maneuver (Right Ventricle): Score 7 | Ability to Reach Areas (Left Atrium): Score 1 | Ability to Reach Areas (Left Atrium): Score 2 | Ability to Reach Areas (Left Atrium): Score 3 | Ability to Reach Areas (Left Atrium): Score 4 | Ability to Reach Areas (Left Atrium): Score 5 | Ability to Reach Areas (Left Atrium): Score 6 | Ability to Reach Areas (Left Atrium): Score 7 | Ability to Reach Areas (Right Atrium): Score 1 | Ability to Reach Areas (Right Atrium): Score 2 | Ability to Reach Areas (Right Atrium): Score 3 | Ability to Reach Areas (Right Atrium): Score 4 | Ability to Reach Areas (Right Atrium): Score 5 | Ability to Reach Areas (Right Atrium): Score 6 | Ability to Reach Areas (Right Atrium): Score 7 | Ability to Reach Areas (Left Ventricle): Score 1 | Ability to Reach Areas (Left Ventricle): Score 2 | Ability to Reach Areas (Left Ventricle): Score 3 | Ability to Reach Areas (Left Ventricle): Score 4 | Ability to Reach Areas (Left Ventricle): Score 5 | Ability to Reach Areas (Left Ventricle): Score 6 | Ability to Reach Areas (Left Ventricle): Score 7 | Ability to Reach Areas (Right Ventricle): Score 1 | Ability to Reach Areas (Right Ventricle): Score 2 | Ability to Reach Areas (Right Ventricle): Score 3 | Ability to Reach Areas (Right Ventricle): Score 4 | Ability to Reach Areas (Right Ventricle): Score 5 | Ability to Reach Areas (Right Ventricle): Score 6 | Ability to Reach Areas (Right Ventricle): Score 7 | Ability to Withdraw (Left Atrium): Score 1 | Ability to Withdraw (Left Atrium): Score 2 | Ability to Withdraw (Left Atrium): Score 3 | Ability to Withdraw (Left Atrium): Score 4 | Ability to Withdraw (Left Atrium): Score 5 | Ability to Withdraw (Left Atrium): Score 6 | Ability to Withdraw (Left Atrium): Score 7 | Ability to Withdraw (Right Atrium): Score 1 | Ability to Withdraw (Right Atrium): Score 2 | Ability to Withdraw (Right Atrium): Score 3 | Ability to Withdraw (Right Atrium): Score 4 | Ability to Withdraw (Right Atrium): Score 5 | Ability to Withdraw (Right Atrium): Score 6 | Ability to Withdraw (Right Atrium): Score 7 | Ability to Withdraw (Left Ventricle): Score 1 | Ability to Withdraw (Left Ventricle): Score 2 | Ability to Withdraw (Left Ventricle): Score 3 | Ability to Withdraw (Left Ventricle): Score 4 | Ability to Withdraw (Left Ventricle): Score 5 | Ability to Withdraw (Left Ventricle): Score 6 | Ability to Withdraw (Left Ventricle): Score 7 | Ability to Withdraw (Right Ventricle): Score 1 | Ability to Withdraw (Right Ventricle): Score 2 | Ability to Withdraw (Right Ventricle): Score 3 | Ability to Withdraw (Right Ventricle): Score 4 | Ability to Withdraw (Right Ventricle): Score 5 | Ability to Withdraw (Right Ventricle): Score 6 | Ability to Withdraw (Right Ventricle): Score 7 | Insertion/ Withdrawal from Introducer Sheath: Score 1 | Insertion/ Withdrawal from Introducer Sheath: Score 2 | Insertion/ Withdrawal from Introducer Sheath: Score 3 | Insertion/ Withdrawal from Introducer Sheath: Score 4 | Insertion/ Withdrawal from Introducer Sheath: Score 5 | Insertion/ Withdrawal from Introducer Sheath: Score 6 | Insertion/ Withdrawal from Introducer Sheath: Score 7 | Learning Curve: Score 1 | Learning Curve: Score 2 | Learning Curve: Score 3 | Learning Curve: Score 4 | Learning Curve: Score 5 | Learning Curve: Score 6 | Learning Curve: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 0 | 0 | 6 | 17 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 3 | 1 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | 9 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 5 | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 12 | 6 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 0 | 0 | 1 | 3 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 15 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 2 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 9 | 9 | 10 | 0 | 0 | 0 | 4 | 4 | 18 | 5 |
Number of responders for physician assessment for pacing (local pacing capture) were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for pacing. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Local pacing capture: Score 1 | Local pacing capture: Score 2 | Local pacing capture: Score 3 | Local pacing capture: Score 4 | Local pacing capture: Score 5 | Local pacing capture: Score 6 | Local pacing capture: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 1 | 1 | 2 | 2 | 3 |
Number of responders for physician assessment for signal collection and quality were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for signal collection and quality (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNIPOLAR signals in Atrium: Score 1 | UNIPOLAR signals in Atrium: Score 2 | UNIPOLAR signals in Atrium: Score 3 | UNIPOLAR signals in Atrium: Score 4 | UNIPOLAR signals in Atrium: Score 5 | UNIPOLAR signals in Atrium: Score 6 | UNIPOLAR signals in Atrium: Score 7 | UNIPOLAR signals in Ventricle: Score 1 | UNIPOLAR signals in Ventricle: Score 2 | UNIPOLAR signals in Ventricle: Score 3 | UNIPOLAR signals in Ventricle: Score 4 | UNIPOLAR signals in Ventricle: Score 5 | UNIPOLAR signals in Ventricle: Score 6 | UNIPOLAR signals in Ventricle: Score 7 | UNIPOLAR noise encountered: Score 1 | UNIPOLAR noise encountered: Score 2 | UNIPOLAR noise encountered: Score 3 | UNIPOLAR noise encountered: Score 4 | UNIPOLAR noise encountered: Score 5 | UNIPOLAR noise encountered: Score 6 | UNIPOLAR noise encountered: Score 7 | BIPOLAR signals in Atrium: Score 1 | BIPOLAR signals in Atrium: Score 2 | BIPOLAR signals in Atrium: Score 3 | BIPOLAR signals in Atrium: Score 4 | BIPOLAR signals in Atrium: Score 5 | BIPOLAR signals in Atrium: Score 6 | BIPOLAR signals in Atrium: Score 7 | BIPOLAR signals in Ventricle: Score 1 | BIPOLAR signals in Ventricle: Score 2 | BIPOLAR signals in Ventricle: Score 3 | BIPOLAR signals in Ventricle: Score 4 | BIPOLAR signals in Ventricle: Score 5 | BIPOLAR signals in Ventricle: Score 6 | BIPOLAR signals in Ventricle: Score 7 | BIPOLAR noise encountered: Score 1 | BIPOLAR noise encountered: Score 2 | BIPOLAR noise encountered: Score 3 | BIPOLAR noise encountered: Score 4 | BIPOLAR noise encountered: Score 5 | BIPOLAR noise encountered: Score 6 | BIPOLAR noise encountered: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 0 | 1 | 4 | 2 | 0 | 0 | 0 | 1 | 3 | 4 | 0 | 0 | 0 | 0 | 1 | 4 | 7 | 4 | 0 | 0 | 0 | 0 | 0 | 7 | 16 | 0 | 0 | 0 | 0 | 1 | 7 | 1 | 0 | 0 | 0 | 1 | 3 | 12 | 15 |
Number of responders for physician assessment for workflow were reported. A post-procedure survey of 11 questions, each with individual sub-questions were asked. Each question/sub-question was answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent). Responders refers to participants with physician assessment for workflow. (NCT04983797)
Timeframe: Up to 72 days
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ability to reduce fluoroscopy: Score 1 | Ability to reduce fluoroscopy: Score 2 | Ability to reduce fluoroscopy: Score 3 | Ability to reduce fluoroscopy: Score 4 | Ability to reduce fluoroscopy: Score 5 | Ability to reduce fluoroscopy: Score 6 | Ability to reduce fluoroscopy: Score 7 | Time for pre-procedure mapping: Score 1 | Time for pre-procedure mapping: Score 2 | Time for pre-procedure mapping: Score 3 | Time for pre-procedure mapping: Score 4 | Time for pre-procedure mapping: Score 5 | Time for pre-procedure mapping: Score 6 | Time for pre-procedure mapping: Score 7 | Time for post-procedure mapping after standard of care ablation: Score 1 | Time for post-procedure mapping after standard of care ablation: Score 2 | Time for post-procedure mapping after standard of care ablation: Score 3 | Time for post-procedure mapping after standard of care ablation: Score 4 | Time for post-procedure mapping after standard of care ablation: Score 5 | Time for post-procedure mapping after standard of care ablation: Score 6 | Time for post-procedure mapping after standard of care ablation: Score 7 | Ability to identify targets: Score 1 | Ability to identify targets: Score 2 | Ability to identify targets: Score 3 | Ability to identify targets: Score 4 | Ability to identify targets: Score 5 | Ability to identify targets: Score 6 | Ability to identify targets: Score 7 | |
| OPTRELL Mapping Catheter | 0 | 0 | 0 | 10 | 6 | 10 | 5 | 0 | 0 | 0 | 8 | 4 | 10 | 9 | 0 | 0 | 0 | 2 | 4 | 9 | 9 | 0 | 0 | 0 | 1 | 0 | 13 | 14 |
Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded after the procedure reflecting the overall pain felt during the procedure. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once 10 minutes after the procedure on the day of recruitment, approximately one minute.
| Intervention | units on a scale (Median) |
|---|---|
| 20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block | 57 |
| 40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block | 56 |
Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded 10 minutes after the completion of the procedure. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once 10 minutes after the procedure on the day of recruitment, approximately one minute.
| Intervention | units on a scale (Median) |
|---|---|
| 20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block | 26 |
| 40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block | 11 |
Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded at time of cervical dilation. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once during the procedure on the day of recruitment, approximately one minute. During procedure at time of cervical dilation.
| Intervention | units on a scale (Median) |
|---|---|
| 20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block | 52 |
| 40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block | 45 |
Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded immediately after uterine aspiration. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once during the procedure on the day of recruitment, approximately 1 minute. During procedure immediately after uterine aspiration.
| Intervention | units on a scale (Median) |
|---|---|
| 20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block | 46 |
| 40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block | 58 |
3 reviews available for mepivacaine and Drug Hypersensitivity
| Article | Year |
|---|---|
Local anesthesia: advances in agents and techniques.
Topics: Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Bupivacaine; Carticaine; Chemistry, Pharm | 2002 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Toxicity of local anaesthetics.
Topics: Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Cocaine; Drug Hypersensitivity; Eti | 2003 |
Physiology and pharmacology of local anesthetic agents.
Topics: Administration, Topical; Amides; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular System; Ce | 1973 |
42 other studies available for mepivacaine and Drug Hypersensitivity
| Article | Year |
|---|---|
Immediate local anesthetic reactions and diagnostic test results in pediatric patients.
Topics: Adolescent; Anesthetics, Local; Child; Child, Preschool; Drug Hypersensitivity; Female; Humans; Hype | 2021 |
Lidocaine as a Rare and Hidden Allergen in the Perioperative Setting: A Case Report.
Topics: Allergens; Drug Hypersensitivity; Drug Interactions; Female; Humans; Lidocaine; Mepivacaine; Middle | 2019 |
Allergic reaction to mepivacaine in a child.
Topics: Adolescent; Anesthetics, Local; Drug Hypersensitivity; Humans; Male; Mepivacaine; Skin Tests | 2013 |
Immediate allergy to mepivacaine.
Topics: Anesthetics, Local; Drug Hypersensitivity; Female; Humans; Mepivacaine; Middle Aged; Skin Tests | 2011 |
Evaluation of adverse reactions to local anesthetics: experience with 236 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Bupivacaine; Child; Child, Preschool | 2003 |
[Emergency axillary brachial plexus block in a patient allergic to atropine].
Topics: Atropine; Axilla; Brachial Plexus; Bronchial Spasm; Child; Contraindications; Drug Hypersensitivity; | 2006 |
Cross-reactivity among amide-type local anesthetics in a case of allergy to mepivacaine.
Topics: Adult; Anesthetics, Local; Cross Reactions; Double-Blind Method; Drug Hypersensitivity; Humans; Immu | 2006 |
Hypersensitivity to procaine, tetracaine, mepivacaine, and methylparaben: report of a case.
Topics: Anesthesia, Dental; Anesthetics, Local; Drug Hypersensitivity; Female; Humans; Mepivacaine; Middle A | 1983 |
[Local anesthesia and Para group allergy].
Topics: Anesthetics, Local; Chemical Phenomena; Chemistry; Drug Hypersensitivity; Humans; Lidocaine; Mepivac | 1983 |
Skin testing after anaphylactoid reactions to dental local anesthetics. A comparison with controls.
Topics: Adolescent; Adult; Aged; Anaphylaxis; Anesthesia, Dental; Anesthetics, Local; Chi-Square Distributio | 1993 |
The evaluation of a reported allergic reaction to an amide local anesthetic: a case report.
Topics: Adult; Amides; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Drug Hypersensitivity; Fem | 1995 |
Allergic reaction caused by local anesthetic agents belonging to the amide group.
Topics: Adult; Allergens; Anesthetics, Local; Drug Hypersensitivity; Female; Humans; Immunoglobulin E; Lidoc | 1997 |
[Immediate allergy to anesthetics of the amide group].
Topics: Anesthetics, Local; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Immediate; Mepivacaine; | 1997 |
How to avoid local anaesthetic toxicity.
Topics: Adult; Aged; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Body Weight; Child; Child, P | 1998 |
Recognition of local anesthetics by alphabeta+ T cells.
Topics: Anesthetics, Local; Cell Line; Clone Cells; Cross Reactions; Drug Hypersensitivity; Epitopes; Humans | 1999 |
Long-term absence of sensitization to mepivacaine as assessed by a diagnostic protocol including patch testing.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Anesthetics, Local; Child; Drug Hypersensitivity; | 2001 |
Evaluating a dental patient for local anesthesia allergy.
Topics: Aged; Allergens; Anesthesia, Dental; Anesthetics, Local; Drug Hypersensitivity; Exanthema; Humans; H | 2002 |
Anaphylaxis due to local anesthesia hypersensitivity: report of case.
Topics: Anaphylaxis; Anesthesia, Dental; Anesthesia, Local; Child; Drug Hypersensitivity; Humans; Male; Mepi | 1978 |
[Allergic reactions caused by mepivacaine (author's transl)].
Topics: Aged; Anesthesia, Epidural; Anesthetics, Local; Drug Hypersensitivity; Humans; Male; Mepivacaine | 1978 |
Vertical pendular nystagmus in chronic myositis of medial and lateral rectus.
Topics: Adult; Chronic Disease; Diplopia; Drug Hypersensitivity; Female; Humans; Lidocaine; Mepivacaine; Myo | 1978 |
[Pseudo-anaphylactic reaction to procaine-penicillin G. 3 cases of Hoigne's syndrome].
Topics: Adult; Anxiety; Blood Pressure; Diagnosis, Differential; Drug Hypersensitivity; Female; Hallucinatio | 1976 |
Deaths from paracervical anesthesia used for first-trimester abortion, 1972-1975.
Topics: Abortion, Induced; Adolescent; Adult; Anesthesia, Obstetrical; Cervix Uteri; Dose-Response Relations | 1976 |
Deaths from paracervical anesthesia used for first-trimester abortion, 1972-1975.
Topics: Abortion, Induced; Adolescent; Adult; Anesthesia, Obstetrical; Cervix Uteri; Dose-Response Relations | 1976 |
Deaths from paracervical anesthesia used for first-trimester abortion, 1972-1975.
Topics: Abortion, Induced; Adolescent; Adult; Anesthesia, Obstetrical; Cervix Uteri; Dose-Response Relations | 1976 |
Deaths from paracervical anesthesia used for first-trimester abortion, 1972-1975.
Topics: Abortion, Induced; Adolescent; Adult; Anesthesia, Obstetrical; Cervix Uteri; Dose-Response Relations | 1976 |
Hypnosis in a dental patient with allergies.
Topics: Adult; Anesthesia, Intravenous; Dental Care; Drug Hypersensitivity; Female; Humans; Hypnosis, Dental | 1976 |
[Clinical and experimental contribution to the pathogenesis of acute life-threatening incidents following neck anesthesia].
Topics: Acute Disease; Anaphylaxis; Anesthesia, Epidural; Anesthesia, Local; Anesthetics; Drug Hypersensitiv | 1975 |
Letter: Allergy to procaine and mepivacaine.
Topics: Drug Hypersensitivity; Humans; Injections, Intravenous; Mepivacaine; Procaine | 1975 |
[Clinical and experimental contribution concerning the pathogenesis of acute life-threatening complications during neck anaesthesia].
Topics: Acute Disease; Aged; Anesthesia, Epidural; Anesthesia, Local; Anesthetics; Animals; Disease Models, | 1975 |
Type IV allergy to amide-type local anesthetics.
Topics: Anesthetics, Local; Cross Reactions; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delaye | 1991 |
[Rare complication of local anesthesia].
Topics: Adult; Ampicillin; Anesthesia, Dental; Anesthesia, Local; Drug Hypersensitivity; Female; Humans; Mep | 1990 |
[Allergologic tests: basophil degranulation in odontostomatology. Method and clinical application].
Topics: Adult; Aged; Anesthesia, Dental; Anesthetics, Local; Basophils; Child; Drug Hypersensitivity; Female | 1988 |
[Degranulation test of basophils with scalar concentrations of 3% carbocaine. Evaluation of clinical cases with test over 40%].
Topics: Adult; Aged; Anesthesia, Dental; Basophils; Drug Hypersensitivity; Female; Humans; Mepivacaine; Midd | 1989 |
[Epidural anaesthesia for multiallergic pregnant patients].
Topics: Adult; Anesthesia, Epidural; Drug Hypersensitivity; Female; Humans; Intradermal Tests; Mepivacaine; | 1988 |
Allergy to lidocaine and mepivacaine: report of a case.
Topics: Adult; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Lidocaine; Male; Mepivacaine | 1985 |
Anaphylactic reaction to lidocaine.
Topics: Adult; Anaphylaxis; Bupivacaine; Drug Evaluation; Drug Hypersensitivity; Female; Humans; Intradermal | 1986 |
[Complications of regional anaesthesia and their treatment (author's transl)].
Topics: Adrenal Cortex Hormones; Anesthesia, Local; Apnea; Barbiturates; Bradycardia; Bupivacaine; Diagnosis | 1973 |
[Toxicology of scandicaine. I. Chemico-toxicological studies].
Topics: Aged; Anesthesia, Local; Anesthetics, Local; Drug Hypersensitivity; Epidermal Cyst; Female; Humans; | 1973 |
[Toxicology of scandicaine. II. Histopathological findings].
Topics: Adult; Anesthesia, Local; Anesthetics, Local; Drug Hypersensitivity; Female; Humans; Mepivacaine; Po | 1973 |
Evaluation of patients with history of allergy to local anesthetic drugs.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Child; Drug Hypersensitivity; Female; Humans; Lidocaine | 1971 |
Serum-type allergic reactions to local anesthetic injections--report of two cases.
Topics: Anesthesia, Dental; Dentistry; Drug Hypersensitivity; Mepivacaine | 1966 |
Angioneurotic edema. Report of a case of the allergic type caused by sensitivity to mepivacaine hydrochloride.
Topics: Adult; Anesthesia, Dental; Anesthesia, Local; Angioedema; Drug Hypersensitivity; Female; Humans; Mep | 1967 |
Hypersensitive reaction to local anesthesia.
Topics: Anesthesia, Dental; Dentistry; Drug Hypersensitivity; Laryngismus; Mepivacaine | 1968 |
[On the frequency of cosmetic complications].
Topics: Accidents, Occupational; Adolescent; Adult; Cosmetics; Drug Hypersensitivity; Female; Humans; Male; | 1968 |
Frequency of general side reactions after regional anaesthesia with mepivacaine.
Topics: Anesthesia, Conduction; Blood Pressure; Cardiovascular System; Drug Hypersensitivity; Epinephrine; H | 1969 |